-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, the journal Clinical Oncology published the results of a clinical study, mainly in patients with metastatic colorectal cancer (mCRC) who failed first-line oxaliplatin-based chemotherapy, the second-line use of FOLFIRI combined with bevacizumab versus FOLFIRI combined with Efficacy of aflibercept therapy
.
.
We analyzed outcomes in patients who received FOLFIRI in combination with bevacizumab or aflibercept as second-line therapy for mCRC between October 2017 and March 2020
.
The analysis included 67 patients who received FOLFIRI plus aflibercept and 83 patients who received FOLFIRI plus bevacizumab
We analyzed outcomes in patients who received FOLFIRI in combination with bevacizumab or aflibercept as second-line therapy for mCRC between October 2017 and March 2020
Among the 150 patients, 75 (50.
The overall response rate (ORR) in the FOLFIRI+aflibercept arm was 13.
The median PFS in the FOLFIRI+bevacizumab group was 8.
6 months, and the median PFS in the FOLFIRI+aflibercept group was 8.
5 months.
There was no significant difference in the median PFS between the two groups (P=0.
752)
.
6 months, and the median PFS in the FOLFIRI+aflibercept group was 8.
5 months.
There was no significant difference in the median PFS between the two groups (P=0.
752)
.
The median PFS in the FOLFIRI+bevacizumab group was 8.
The median OS of patients in the FOLFIRI+bevacizumab group was 12.
4 months, while the median OS of patients in the FOLFIRI+aflibercept group was 13.
7 months, and there was no significant difference in OS between the two groups (P=0.
276)
.
4 months, while the median OS of patients in the FOLFIRI+aflibercept group was 13.
7 months, and there was no significant difference in OS between the two groups (P=0.
276)
.
The median OS of patients in the FOLFIRI+bevacizumab group was 12.
Treatment-related adverse events of any grade were reported in 86.
5 % of patients treated with FOLFIRI plus aflibercept and in 83.
1 % of patients treated with FOLFIRI plus bevacizumab
.
Grade 3 or 4 adverse events were reported in 11.
Treatment-related adverse events of any grade were reported in 86.
In conclusion, the study showed that the efficacy of FOLFIRI combined with bevacizumab was comparable to that of FOLFIRI combined with aflibercept in the second-line treatment of metastatic colorectal cancer (mCRC)
.
.
Studies have shown that FOLFIRI combined with bevacizumab is comparable to FOLFIRI combined with aflibercept in the second-line treatment of metastatic colorectal cancer (mCRC)
Original source:
Original source:Jo H, Lee MS, Lee YP, Kim H, Hong JY, Lee J, Park SH, Park JO, Park YS, Lim HY, Kang WK, Kim ST.
Jo H, Lee MS, Lee YP, Kim H, Hong JY, Lee J, Park SH, Park JO, Park YS, Lim HY, Kang WK, Kim ST.
A Comparison of Folinic Acid, Fluorouracil and Irinotecan (FOLFIRI) plus Bevacizumab and FOLFIRI plus Aflibercept as Second-line Treatment for Metastatic Colorectal Cancer.
Clin Oncol (R Coll Radiol).
2022 Mar 2:S0936-6555(22)00095-4.
doi: 10.
1016/j.
clon.
2022.
02.
011.
Epub ahead of print.
PMID: 35248464.
Leave a message here
